NasdaqGM - Delayed Quote USD

Trevi Therapeutics, Inc. (TRVI)

2.7800 +0.2400 (+9.45%)
At close: April 26 at 4:00 PM EDT
2.7800 0.00 (0.00%)
After hours: April 26 at 4:20 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Operating Expense
33,923.0000
33,923.0000
29,907.0000
32,476.0000
32,489.0000
Operating Income
-33,923.0000
-33,923.0000
-29,907.0000
-32,476.0000
-32,489.0000
Net Non Operating Interest Income Expense
4,357.0000
4,357.0000
577.0000
-1,192.0000
-278.0000
Other Income Expense
469.0000
469.0000
142.0000
-293.0000
-9.0000
Pretax Income
-29,097.0000
-29,097.0000
-29,188.0000
-33,961.0000
-32,776.0000
Tax Provision
-32.0000
-32.0000
-36.0000
-21.0000
-18.0000
Net Income Common Stockholders
-29,065.0000
-29,065.0000
-29,152.0000
-33,940.0000
-32,758.0000
Diluted NI Available to Com Stockholders
-29,065.0000
-29,065.0000
-29,152.0000
-33,940.0000
-32,758.0000
Basic EPS
-0.29
--
-0.45
-1.49
-1.81
Diluted EPS
-0.29
--
-0.45
-1.49
-1.81
Basic Average Shares
99,033.3730
--
64,541.9110
22,841.4810
18,059.0110
Diluted Average Shares
99,033.3730
--
64,541.9110
22,841.4810
18,059.0110
Total Operating Income as Reported
-33,923.0000
-33,923.0000
-29,907.0000
-32,476.0000
-32,489.0000
Total Expenses
33,923.0000
33,923.0000
29,907.0000
32,476.0000
32,489.0000
Net Income from Continuing & Discontinued Operation
-29,065.0000
-29,065.0000
-29,152.0000
-33,940.0000
-32,758.0000
Normalized Income
-29,065.0000
-29,065.0000
-29,005.1470
-34,021.9180
-32,749.0090
Interest Income
4,748.0000
4,748.0000
1,740.0000
10.0000
178.0000
Interest Expense
391.0000
391.0000
1,163.0000
1,202.0000
456.0000
Net Interest Income
4,357.0000
4,357.0000
577.0000
-1,192.0000
-278.0000
EBIT
-28,706.0000
-28,706.0000
-28,025.0000
-32,759.0000
-32,320.0000
EBITDA
-28,583.0000
-28,583.0000
-27,982.0000
-32,709.0000
-32,273.0000
Reconciled Depreciation
123.0000
123.0000
43.0000
50.0000
47.0000
Net Income from Continuing Operation Net Minority Interest
-29,065.0000
-29,065.0000
-29,152.0000
-33,940.0000
-32,758.0000
Total Unusual Items Excluding Goodwill
-94.0000
--
-147.0000
82.0000
-9.0000
Total Unusual Items
-94.0000
--
-147.0000
82.0000
-9.0000
Normalized EBITDA
-28,583.0000
-28,583.0000
-27,835.0000
-32,791.0000
-32,264.0000
Tax Rate for Calcs
0.0000
0.0000
0.0000
0.0000
0.0000
Tax Effect of Unusual Items
--
--
-0.1470
0.0820
-0.0090
12/31/2020 - 5/7/2019

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

TNYA Tenaya Therapeutics, Inc.
4.3100
+2.13%
 
RLYB Rallybio Corporation
1.7000
+3.03%
 
BCAB BioAtla, Inc.
2.5400
+12.89%
 
AVTE Aerovate Therapeutics, Inc.
21.75
+0.83%
 
TSHA Taysha Gene Therapies, Inc.
2.3900
+3.91%
 
EPIX ESSA Pharma Inc.
6.08
-0.65%
 
MRSN Mersana Therapeutics, Inc.
2.9400
+3.16%
 
PASG Passage Bio, Inc.
1.3200
+8.20%
 
TARA Protara Therapeutics, Inc.
2.9250
-4.10%
 
VINC Vincerx Pharma, Inc.
0.7300
-18.59%